BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25030619)

  • 1. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.
    Thies ED; Tanase K; Maeder U; Luster M; Buck AK; Hänscheid H; Reiners C; Verburg FA
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2281-90. PubMed ID: 25030619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients.
    Verburg FA; Mäder U; Reiners C; Hänscheid H
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4487-96. PubMed ID: 25259907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer.
    Verburg FA; Mäder U; Luster M; Hänscheid H; Reiners C
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1390-8. PubMed ID: 26070546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
    Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
    Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma.
    Czepczyński R; Ziemnicka K; Baczyk M; Oleksa R; Ruchała M; Sowiński J
    Thyroid; 2005 Nov; 15(11):1261-5. PubMed ID: 16356090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Only a Rapid Complete Biochemical Remission After 131I-Therapy is Associated with an Unimpaired Life Expectancy in Differentiated Thyroid Cancer.
    Verburg FA; Mäder U; Grelle I; Giovanella L; Reiners C; Hänscheid H
    Horm Metab Res; 2017 Nov; 49(11):860-868. PubMed ID: 29136675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
    Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
    J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma.
    Sabet A; Binse I; Dogan S; Koch A; Rosenbaum-Krumme SJ; Biersack HJ; Biermann K; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):190-195. PubMed ID: 27530124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
    Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
    Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
    Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
    J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
    Ma C; Xie J; Kuang A
    J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of radioiodine therapy in thyroid cancer patients with recent contrasted computed tomography.
    Rodriguez JD; Kirk D; Benefield T; Maygarden SJ; Pou K; Kim LT; Hackman TG; Khandani AH
    Nucl Med Commun; 2020 Mar; 41(3):228-234. PubMed ID: 31895755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic
    Trevizam PG; Tagliarini JV; Castilho EC; de Alencar Marques M; Kiy Y; Mazeto GMFS
    Endocr Res; 2017 Feb; 42(1):42-48. PubMed ID: 27144920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study.
    Wang R; Zhang Y; Tan J; Zhang G; Zhang R; Zheng W; He Y
    Medicine (Baltimore); 2017 May; 96(19):e6809. PubMed ID: 28489758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up.
    Biko J; Reiners C; Kreissl MC; Verburg FA; Demidchik Y; Drozd V
    Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):651-5. PubMed ID: 21113590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value and optimal threshold of first thyroglobulin in low/intermediate risk DTC.
    Zakavi SR; Ayati N; Zare S; Ayati A; Sadri K; Fekri N; Abbasi B; Shafiei S
    Q J Nucl Med Mol Imaging; 2021 Mar; 65(1):64-71. PubMed ID: 30916533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative remnant
    Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
    Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.